<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="332">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361942</url>
  </required_header>
  <id_info>
    <org_study_id>TerCel_007</org_study_id>
    <secondary_id>2020-001682-36</secondary_id>
    <nct_id>NCT04361942</nct_id>
  </id_info>
  <brief_title>Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)</brief_title>
  <acronym>COVID_MSV</acronym>
  <official_title>Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Citospin</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Valladolid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Castilla-León Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital del Río Hortega</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Novel coronavirus COVID-19 has become a health emergency around the world. Since first
      patients were detected in Wuhan China, in December 2019, COVID-19 has spread quickly
      worldwide, being a severe threat to public health. Fever, dry cough, shortness of breath and
      breathing distress are the main characteristics of COVID-19 infection. Some patients develop
      overwhelming lung inflammation and acute respiratory failure, for which there is no specific
      therapy. Therefore, safe and effective treatment for COVID-19 pneumonia is utterly necessary,
      mainly in critical cases. Mesenchymal stem cells (MSCs) have been widely used in the
      immune-mediated inflammatory diseases. MSCs can regulate both innate and adaptive immunity by
      suppressing the proliferation, differentiation and activation of different cells. These
      immunomodulatory properties of MSCs support performance of the phase I/II, placebo-
      controlled, randomized MSCs for treatment of severe COVID-19 pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Novel coronavirus COVID-19 has spread quickly from Wuhan China to worldwide. On 15 April
      2020, the World Health Organization (WHO) has reported 1.914.916 confirmed cases and 123.010
      deaths globally, being a severe threat to public health.

      Some patients develop overwhelming lung inflammation and acute respiratory failure. Several
      reports demonstrated that COVID-19 specifically recognized the angiotensin I converting ezyme
      2 repector (ACE2) and ACE2-positive cells are infected by the virus. ACE2 receptor is widely
      present on the human cells surface such as alveolar type II cells and capillary endothelium,
      among others. COVID-19 infects cells and stimulates a terrible cytokine storm in the lung
      followed by edema, dysfunction of the air exchange and acute respiratory distress which may
      lead to death. Further, once COVID-19 enters in blood circulation, it can easy spread to some
      systems and organs, causing significant damage. Under these circumstances, it is reasonable
      to believe that the inhibition of inflammatory response is the key to treat COVID-19
      pneumonia.

      Mesenchymal stem cells (MSCs) have been widely used in the immune-mediated inflammatory
      diseases. MSCs can regulate both innate and adaptive immunity by suppressing the
      proliferation, differentiation and activation of different cells. Some studies have shown
      that MSCs can significantly reduce acute lung injury in mice caused by H9N2 and H5N1 virus,
      reducing proinflammatory cytokines and inflammatory cells into the lungs.

      These immunomodulatory properties of MSCs support performance of the Phase I/II, double-blind
      (neither the participant nor the investigator will know if active drug or placebo is
      assigned), placebo-controlled, randomized (assigned by chance), in which subjects with severe
      COVID-19 pneumonia shall be received either MSCs (1 million cells/kg) or placebo by
      intravenous injection. The administration of cells will be done only once.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Both experimental and Placebo will receive a similar endovenous injection with either cells or placebo. Blind to participant, investigator ans care providers</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who have achieved withdrawal of invasive mechanical ventilation</measure>
    <time_frame>0-7 days</time_frame>
    <description>Index of therapy success to preserve Intensive Care Hospitalization space</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of mortality</measure>
    <time_frame>28 days</time_frame>
    <description>To measure global success</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have achieved clinical response</measure>
    <time_frame>0-7days</time_frame>
    <description>Index based in the 4 most relevant symptoms and signs: fever, shortness of bread, %Hemoglobin Saturation and PaO2 / FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who have achieved radiological responses</measure>
    <time_frame>0-28 days</time_frame>
    <description>Evaluation of pneumonia changes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood white cell counts and their subpopulations.</measure>
    <time_frame>0-180 days</time_frame>
    <description>Haemogram and cell subpopulations</description>
  </other_outcome>
  <other_outcome>
    <measure>Cellular markers of inflammation</measure>
    <time_frame>0-180 days</time_frame>
    <description>Lymphocyte profiles, CD3, CD19, CD16+CD56, CD4/CD8, Tregs</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytokines and chemokines in peripheral blood</measure>
    <time_frame>0-180 days</time_frame>
    <description>IL-10, IL-6, IP-10, TNF-alpha</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injection of 1 million MSV cells/Kg in 100 ml of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous injection of 100 ml of saline containing no cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stromal Cells</intervention_name>
    <description>Intravenous injection of 1 million MSV cells/Kg diluted in 100 ml saline</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>MSV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous injection of 100 ml saline containing no cells</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women or men of ≥ 18 years of age

          2. SARS-CoV-2 infection confirmed by molecular testing.

          3. Admitted to the Intensive Care Unit with pneumonia by COVID-19 infection in the last
             48 hours, that meet at least one of these criteria:

               1. Respiratory distress.

               2. Respiratory rate (FR) ≥ 30 rpm.

               3. Basal oxygen saturation at rest ≤ 93%.

               4. Arterial partial pressure of oxygen (PaO₂) / inspiratory fraction of oxygen
                  (FiO₂) ≤300mmHg

          4. Consent of the patient or his legal representative for participation in the study.

        Exclusion Criteria:

          1. Active tumor disease.

          2. Pregnancy.

          3. Participation in another clinical trial for the same pathology.

          4. Any circumstance that in the researcher's opinion justifies the patient's
             non-participation in the trial.

          5. Lack of signed consent for participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Barbado, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Río Hortega, Valladolid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa Conde, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Río Hortega, Valladolid, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margarita González-Vallinas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Valladolid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Barbado, MD,PhD</last_name>
    <phone>+34 616 73 40 03</phone>
    <email>jbarbadoa@saludcastillayleon.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosa Conde, MD, PhD</last_name>
    <phone>+34 608 21 28 65</phone>
    <email>rconvi@saludcastillayleon.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Barbado, MD, PhD</last_name>
      <phone>+34 983 420400</phone>
      <email>jbarbadoa@saludcastillayleon.es</email>
    </contact>
    <contact_backup>
      <last_name>Rosa Conde, MD, PhD</last_name>
      <phone>+34 983 420400</phone>
      <email>'Rosa Conde Vicente' &lt;rconvi@saludcastillayleon.es&gt;</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Vega A, Martín-Ferrero MA, Del Canto F, Alberca M, García V, Munar A, Orozco L, Soler R, Fuertes JJ, Huguet M, Sánchez A, García-Sancho J. Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial. Transplantation. 2015 Aug;99(8):1681-90. doi: 10.1097/TP.0000000000000678.</citation>
    <PMID>25822648</PMID>
  </results_reference>
  <results_reference>
    <citation>Noriega DC, Ardura F, Hernández-Ramajo R, Martín-Ferrero MÁ, Sánchez-Lite I, Toribio B, Alberca M, García V, Moraleda JM, Sánchez A, García-Sancho J. Intervertebral Disc Repair by Allogeneic Mesenchymal Bone Marrow Cells: A Randomized Controlled Trial. Transplantation. 2017 Aug;101(8):1945-1951. doi: 10.1097/TP.0000000000001484.</citation>
    <PMID>27661661</PMID>
  </results_reference>
  <results_reference>
    <citation>Barbado J, Tabera S, Sánchez A, García-Sancho J. Therapeutic potential of allogeneic mesenchymal stromal cells transplantation for lupus nephritis. Lupus. 2018 Nov;27(13):2161-2165. doi: 10.1177/0961203318804922. Epub 2018 Oct 5.</citation>
    <PMID>30290717</PMID>
  </results_reference>
  <results_reference>
    <citation>Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K, Zhao RC. Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020 Mar 9;11(2):216-228. doi: 10.14336/AD.2020.0228. eCollection 2020 Apr.</citation>
    <PMID>32257537</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Mesenchymal Stromal Cells</keyword>
  <keyword>MSV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

